ABMT — Advanced Biomedical Technologies Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Market Cap
$0.03m
Enterprise Value
$6.37m
Revenue
$0.12m

Annual income statement for Advanced Biomedical Technologies, fiscal year end - October 31st, USD millions except per share, conversion factor applied.

	2016 October 31st	2017 October 31st	2018 October 31st	2019 October 31st	2020 October 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	0	0	0	0.012	0.124
Cost of Revenue
Gross Profit	—	—	—	0.004	0.072
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	0.461	0.404	0.634	0.616	0.57
Operating Profit	-0.461	-0.404	-0.634	-0.605	-0.447
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-0.725	-0.692	-0.953	-0.949	-0.672
Provision for Income Taxes
Net Income After Taxes	-0.725	-0.692	-0.953	-0.949	-0.672
Minority Interest
Net Income Before Extraordinary Items
Net Income	-0.725	-0.692	-0.953	-0.949	-0.672
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-0.725	-0.692	-0.953	-0.949	-0.672
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.011	-0.01	-0.014	-0.014	-0.01